We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) said Monday that results from a phase III, randomized, double-blind, multicenter clinical study showed blood-disorder drug Luspatercept "achieved a highly statistically significant improvement in the primary endpoint of erythroid response."
According to the companies, the test results showed a significant reduction in transfusion burden compared to a placebo and the safety profile was generally consistent with previously reported data.
The companies also said "the drug achieved primary and all key secondary endpoints in phase III 'BELIEVE' study in adults with transfusion-dependent beta-thalassemia and all key secondary endpoints in phase III 'BELIEVE' study in adults with transfusion-dependent beta-thalassemia."
The companies plan to submit regulatory applications for Luspatercept in the U.S. and Europe in the first half of 2019.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 09, 2018 18:05 ET (22:05 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
